Ardea Biosciences — Corporate Update (October 2009)
25 slides from Ardea Biosciences's corporate update, Oct 19, 2009
Slide 1: Company Update October 19, 2009
Company Update October 19, 2009
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results
Slide 3: Status of Development Programs
Status of Development Programs RDEA427 RDEA806 RDEA119 RDEA119/ RDEA436 Discovery Preclinical Phase 0/1 Phase 2 A B Phase 3 NNRTI for HIV NNRTI for HIV MEKI for cancer Inflammation 3 Gout RDEA594 RDEA684 MEKI + sorafenib for cancer RDEA119 Gout Partnered with Bayer
Slide 4: Gout/Hyperuricemia
Gout/Hyperuricemia Ardea) Biosciences
Slide 5: Hyperuricemia/Gout - Unmet Medical Need
Hyperuricemia/Gout - Unmet Medical Need Gout is caused by abnormally elevated levels of uric acid (>6.8 mg/dL) Painful and debilitating disease Attacks of severe pain/Inflammation Disfiguring nodules (tophi) Kidney damage (nephropathy) Increasing incidence and severity in U.S. (> 5,000,000 potential
Slide 6: Uric Acid Production and Elimination
Hare, J. M. et al. Circulation 2003;107:1951-1953 Uric Acid Production and Elimination Allopurinol Febuxostat RDEA594 Probenecid Benzbromarone* 6 *Benzbromarone is a URAT1 inhibitor approved outside of the US and later withdrawn due to liver toxicity. Pegloticase
Slide 7: Selective URAT1 Transporter Inhibition: The Next Breakthrough in the Treatment of Hyperuricemia/Gout
7 Selective URAT1 Transporter Inhibition: The Next Breakthrough in the Treatment of Hyperuricemia/Gout URAT1 inhibitors Normalize renal clearance of uric acid (90% of gout patients are under-excretors) Induce sustained reduction of serum urate (sUA) level Have been successfully combined with xanthin
Slide 8: Important Commercial Opportunities for URAT1 Inhibitor
Important Commercial Opportunities for URAT1 Inhibitor Monotherapy inadequate responders to allopurinol patients who are intolerant to allopurinol first-line treatment (not primary target) Combination with allopurinol 60% of allopurinol patients don't achieve adequate reduction in uric acid Potentia
Slide 9: Uric Acid-Lowering Was Noticed With RDEA806
Uric Acid-Lowering Was Noticed With RDEA806 Up to 45% reductions in serum urate (sUA) were observed in healthy volunteers in the 10-day multiple ascending dose study Uric acid reductions of were also observed in all HIV patients in the Phase 2a monotherapy study with RDEA806 A 28-day proof-of-concep
Slide 10: RDEA594 Preclinical and Phase Summary
RDEA594 Preclinical and Phase 1 Summary RDEA594 is a selective inhibitor of the URAT1 renal transporter (EC50 = 5-10 ^M) without antiviral activity No effect on OAT1 and OAT3 transporters (no interaction with antivirals or other drugs secreted by these transporters) Limited metabolism by CYP450 Inhi
Slide 11: RDEA594 Phase 2a Pilot Pharmacodynamic and Safety Study in Gout Patients
Arm 1:RDEA594 200 mg QD Screening Period Colchicine Treatment Randomize if no gout flare during 2 weeks of colchicine Off drug Off drug Arm 2: Placebo 400 mg QD Off drug Arm 3: Allopurinol 300 mg 5 pts 5 pts 11 pts 7-21 days 1 week 2 weeks total with dose escalation of RDEA594 after Week 1 1 week Po
Slide 12: Baseline Demographics
Baseline Demographics Baseline Demographics 12
Slide 13: Both Active Arms Produced Significant Reductions in sUA
(CHART) Randomized Drug Washout Period All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers Response defined as < 6.0 mg/dL Placebo % (n/N) RDEA594 % (n/N) Allop
Slide 14: Allopurinol Results From RDEA594 Phase 2a Inconsistent with Previous Studies
Allopurinol Results From RDEA594 Phase 2a Inconsistent with Previous Studies 14 Febuxostat Phase 3 Study Results Febuxostat Phase 3 Study Results Febuxostat Phase 3 Study Results RDEA594 Phase 2a Results APEX 28-Week Study FACT 52-week Study CONFIRMS 28-Week Study RDEA594 Phase 2a Results Allopurino
Slide 15: 83% Response in Renally Impaired Patients Observed with RDEA594
(CHART) 83% Response in Renally Impaired Patients Observed with RDEA594 All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subje
Slide 16: RDEA594 Normalizes Uric Acid Excretion
(CHART) (CHART) RDEA594 Normalizes Uric Acid Excretion Overall results confirm dose selection for Phase 2b Keeping renal excretion of uric acid at normal levels should minimize risk of stones 16
Slide 17: Adverse Events Summary
Treatment Group Mild Moderate Severe Serious Adverse Event Treatment Group (grade 1) (grade 2) (grade 3) Serious Adverse Event Treatment Group N Number of Adverse Events (Number of patients, n/N) Number of Adverse Events (Number of patients, n/N) Number of Adverse Events (Number of patients, n/N) Nu
Slide 18: RDEA594 Phase 2a Pilot Study in Gout Patients - Cohort 2 Enrolling
Arm 1:RDEA594 200 mg QD Screening Period Colchicine Treatment Randomize if no gout flare during 2 weeks of colchicine Off drug Off drug Arm 2: Placebo 400 mg QD Off drug Arm 3: Allopurinol 300 mg 5 pts 5 pts 11 pts 7-21 days 1 week 2 weeks total with dose escalation of RDEA594 after Week 1 1 week Po
Slide 19: RDEA594 Phase 2b Monotherapy Dose-Response, Safety and Efficacy Study - Enrolling
RDEA594 Phase 2b Monotherapy Dose- Response, Safety and Efficacy Study - Enrolling 21 days 2 weeks 4 weeks 2 weeks Population: gout patients with hyperuricemia (serum uric acid ^8 mg/dL) total of 140 patients in 4 treatment arms Duration: 8 wks: 2-wk run-in, 4-wk treatment, 2-wk follow-up: dose will
Slide 20: RDEA594 Phase 2b Allopurinol Add-On Combination Study - Enrolling
RDEA594 Phase 2b Allopurinol Add-On Combination Safety and Efficacy Study - Enrolling Dose Escalation Based on sUA Lowering with 200 mg RDEA594: 18 patients initially, including 12 patients randomized to RDEA594 and 6 patients randomized to placebo 20 RDEA594 100 mg and 300 mg or placebo plus allopu
Slide 21: RDEA594-204: Renal Impairment in Patients with Gout and Hyperuricemia - Screening
RDEA594-204: Renal Impairment in Patients with Gout and Hyperuricemia - Screening Cohort 1A: (6 subjects) 200 mg RDEA594 Subjects must have moderate renal impairment defined as creatinine clearance from (CrCL) ^ 30 mL/min to < 60 mL/min. Subjects will receive RDEA594 once daily for 5 days. Cohorts 1
Slide 22: RDEA594-105: Febuxostat Drug-Drug Interaction and PD Study - Screening
RDEA594-105: Phase 1 Febuxostat Drug-Drug Interaction and PD Study - Screening Population: Up to 54 normal healthy volunteers with sUA ^ 6 mg/dL; 18 per panel Males and postmenopausal or sterile women 18 - 65 years of age, inclusive Up to 3 panels with escalating doses of RDEA594 or placebo - 200 mg
Slide 23: Gout/Hyperuricemia Program Summary
23 There is a large unmet need for new treatments for this debilitating disease RDEA594, a selective URAT1 transport inhibitor, targets the physiologic cause of the vast majority of patients with hyperuricemia: uric acid under- excretion Clinical proof-of-concept has been achieved, with statisticall
Slide 24: Financial Position Summary
Financial Position Summary Statement of Operations (In thousands, except per share data) Six Months Ended June 30, 2009 Revenue Operating expenses Other income (expense) $ 5,512 27,124 (454) NET LOSS $(22,066) NET LOSS PER SHARE $(1.23) 18.3 million common shares outstanding Expect 2009 year-end cas
Slide 25: Near-Term Anticipated Milestones
Near-Term Anticipated Milestones Near-Term Anticipated Milestones 25